Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2

Aguilar,Cristina; Aguilar,Cecilia; Lopez-Marure,Rebeca; Jiménez-Sánchez,Alejandro; Rocha-Zavaleta,Leticia

doi:10.3892/mmr.2014.2044

Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2

Authors:
- Cristina Aguilar
- Cecilia Aguilar
- Rebeca Lopez-Marure
- Alejandro Jiménez-Sánchez
- Leticia Rocha-Zavaleta
View Affiliations

Affiliations: Instituto de Investigaciones Biomédicas, Departamento de Biología Molecular y Biotecnología, UNAM, Ciudad Universitaria, C.P. 04510, Mexico City, Mexico, Instituto Nacional de Cardiología ‘Ignacio Chávez’, Departamento de Biología Celular, Colonia Sección 16, Tlalpan, C.P. 14080, Mexico City, Mexico
Published online on: March 12, 2014 https://doi.org/10.3892/mmr.2014.2044
Pages: 1895-1902

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cytokines erythropoietin (Epo) and stem cell factor (SCF), coupled with the cooperation between their receptors (EpoR and c-Kit), are essential components of normal physiological erythropoiesis. In earlier studies, we demonstrated the expression of c-Kit and EpoR in cervical cancer cells. It was identified that SCF is a survival factor, whereas Epo promotes cell proliferation. Cooperation between EpoR and SCF in cervical cancer has rarely been studied, despite the fact that cell migration and anchorage independent growth are considered initial steps in metastasis. Thus, the aim of this study was to analyse the effect of SCF and Epo alone, or in combination, on the migration and anchorage independent growth of two cervical cancer-derived cell lines. First, we demonstrated the expression of EpoR and c-Kit in the cell lines. Next, we evaluated anchorage independent growth, and identified that Epo and SCF produced a modest number of colonies, whereas the combination Epo/SCF induced a significantly higher number of colonies. Migration was then evaluated in Boyden chambers. Co-stimulation with Epo/SCF induced a significantly higher number of migrating cells than either cytokine alone. SCF-, Epo- and Epo/SCF-induced migration was inhibited by blocking phosphorylation of Janus kinase 2 (JAK2). Accordingly, western blot analysis demonstrated that the JAK2/signal transducer and activator of transcription-5 (STAT5) axis was activated in all cases. By contrast, inhibition of extracellular signal-related kinase (ERK) 1/2 abrogated migration induced by SCF and Epo/SCF only. Concurrently, Epo induced a modest, transient activation of ERK1/2, whereas SCF and Epo/SCF prompted a strong, sustained phosphorylation of ERK1/2. The results from this study have revealed that co-stimulation with Epo/SCF promotes migration and anchorage independent cell growth, and that co-signalling from EpoR and c-Kit converge on JAK2/STAT5 activation. Furthermore, SCF- and Epo/SCF-induced migration depends on the sustained activation of ERK1/2. These results indicate that co-signalling from different cytokine receptors induces migration, and this suggests that migratory behaviour may be regulated by the cooperative activity of Epo and SCF in cells expressing their cognate receptors.

View Figures

View References

1	Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O and Ihle JN: JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 74:227–236. 1993. View Article : Google Scholar : PubMed/NCBI
2	Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A and Sawyer ST: Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood. 93:3757–3773. 1999.PubMed/NCBI
3	Sokolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C and Lodish HF: Ineffective erythropoiesis in Stat5a(−/−)5b(−/−) mice due to decreased survival of early erythroblasts. Blood. 98:3261–3273. 2001.PubMed/NCBI
4	Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL and Krystal G: Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J. 14:5557–5568. 1995.PubMed/NCBI
5	Blume-Jensen P, Janknecht R and Hunter T: The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol. 8:779–782. 1998. View Article : Google Scholar : PubMed/NCBI
6	Krystal GW, DeBerry CS, Linnekin D and Litz J: Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family inhibitor PP1. Cancer Res. 58:4660–4666. 1998.PubMed/NCBI
7	Sundström M, Alfredsson J, Olsson N and Nilsson G: Stem cell factor-induced migration of mast cells requires p38 mitogen-activated protein kinase activity. Exp Cell Res. 267:144–151. 2001.PubMed/NCBI
8	Maddens S, Charruyer A, Plo I, Dubreuil P, Berger S, Salles B, Laurent G and Jaffrézou JP: Kit signalling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect. Blood. 100:1294–1301. 2002.PubMed/NCBI
9	Trieselmann NZ, Soboloff J and Berger SA: Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol Life Sci. 60:759–766. 2003. View Article : Google Scholar : PubMed/NCBI
10	Wu H, Klingmüller U, Besmer P and Lodish HF: Interaction of the erythropoietin and stem-cell-factor receptors. Nature. 377:242–246. 1995. View Article : Google Scholar : PubMed/NCBI
11	Wu H, Klingmüller U, Acurio A, Hsiao JG and Lodish HF: Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc Natl Acad Sci USA. 94:1806–1810. 1997. View Article : Google Scholar : PubMed/NCBI
12	Hong L, Ramdas B, Chen J, Harris C, Wojchowski DM and Kapur R: KIT associated intracellular tyrosines play an essential role in EpoR co-signalling. Cell Signal. 20:1513–1520. 2008. View Article : Google Scholar : PubMed/NCBI
13	Farrell F and Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 9(Suppl 5): 18–30. 2004. View Article : Google Scholar : PubMed/NCBI
14	Horie K, Fujita J, Takakura K, Kanzaki H, Suginami H, Iwai M, Nakayama H and Mori T: The expression of c-kit protein in human adult and fetal tissues. Hum Reprod. 8:1955–1962. 1993.PubMed/NCBI
15	Shenouda G, Mehio A, Souhami L, Duclos M, Portelance L, Belenkov A and Chow T: Erythropoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. Int J Gynecol Cancer. 16:752–756. 2006. View Article : Google Scholar : PubMed/NCBI
16	Caceres-Cortes JR, Alvarado-Moreno JA, Waga K, Rangel-Corona R, Monroy-Garcia A, Rocha-Zavaleta L, Urdiales-Ramos J, Weiss-Steider B, Haman A, Hugo P, et al: Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Res. 61:6281–6289. 2001.PubMed/NCBI
17	Lopez TV, Lappin TR, Maxwell P, Shi Z, Lopez-Marure R, Aguilar C and Rocha-Zavaleta L: Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. Int J Cancer. 129:2566–2576. 2011. View Article : Google Scholar
18	Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G and Verma A: Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia. 7:537–543. 2005. View Article : Google Scholar : PubMed/NCBI
19	Lester RD, Jo M, Campana WM and Gonias SL: Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem. 280:39273–39277. 2005. View Article : Google Scholar
20	Hamadmad SN and Hohl RJ: Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. J Pharmacol Exp Ther. 324:1227–1233. 2008. View Article : Google Scholar
21	Fraser JK, Lin FK and Berridge MV: Expression and modulation of specific, high affinity binding sites for erythropoietin on the human erythroleukemic cell line K562. Blood. 71:104–109. 1988.PubMed/NCBI
22	Fujisue Y, Nakagawa T, Takahara K, Inamoto T, Kiyama S, Azuma H and Asahi M: Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines. Oncol Lett. 5:1765–1770. 2013.PubMed/NCBI
23	Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, Acs G and Xu X: Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene. 31:1649–1660. 2012. View Article : Google Scholar : PubMed/NCBI
24	Steinmann K, Richter AM and Dammann RH: Epigenetic silencing of erythropoietin in human cancers. Genes Cancer. 2:65–73. 2011. View Article : Google Scholar : PubMed/NCBI
25	Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ and Feldman L: An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res. 7:1150–1157. 2009. View Article : Google Scholar : PubMed/NCBI
26	Inoue M, Kyo S, Fujita M, Enomoto T and Kondoh G: Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 54:3049–3053. 1994.PubMed/NCBI
27	Kapur R, Cooper R, Zhang L and Williams DA: Cross-talk between alpha(4)beta(1)/alpha(5)beta(1) and c-Kit results in opposing effect on growth and survival of hematopoietic cells via the activation of focal adhesion kinase, mitogen-activated protein kinase, and Akt signalling pathways. Blood. 97:1975–1981. 2001. View Article : Google Scholar
28	Yang FC, Kapur R, King AJ, Tao W, Kim C, Borneo J, Breese R, Marshall M, Dinauer MC and Williams DA: Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity. 12:557–568. 2000. View Article : Google Scholar : PubMed/NCBI
29	Fraser L, Taylor AH and Forrester LM: SCF/KIT inhibition has a cumulative but reversible effect on the self-renewal of embryonic stem cells and on the survival of differentiating cells. Cell Reprogram. 15:259–268. 2013.PubMed/NCBI
30	Liu L, Zhang X, Do C, Zhang X, Hou N, Zhao D, Sun J, Li L, Wang X and Ma C: MEK1-independent activation of MAPK and MEK1-dependent activation of p70 S6 kinase by stem cell factor (SCF) in ovarian cancer cells. Biochem Biophys Res Commun. 382:385–389. 2009. View Article : Google Scholar : PubMed/NCBI
31	Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G and Rodeck U: Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res. 61:2200–2206. 2001.PubMed/NCBI
32	Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M and Lappin TR: Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res. 8:615–626. 2010. View Article : Google Scholar : PubMed/NCBI
33	Wu H, Klingmüller U, Bersmer P and Lodish HF: Interaction of the erythropoietin and stem-cell-factor receptors. Nature. 377:242–246. 1995. View Article : Google Scholar : PubMed/NCBI
34	Grebier F, Kerenyi MA, Kovacic B, Kolbe T, Becker V, Dolznig H, Pfeffer K, Klingmüller U, Müller M, Beug H, et al: Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood. 111:4511–4522. 2008. View Article : Google Scholar : PubMed/NCBI
35	Sui X, Krantz SB, You M and Zhao Z: Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood. 92:1142–1149. 1998.PubMed/NCBI